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Introductory note
The information presented in this report is based on data collection within large, probabilistic, 
nationally representative general population surveys. It can be found in part in the EMCDDA 
Statistical bulletins and Annual reports, but this is the first time that the data have been brought 
together and presented in a comprehensive and integrated way.
For the purpose of this report, ‘daily cannabis use’ is considered as the use of cannabis for 20 days 
or more in the last 30 days (also called ‘daily or almost daily use’ or sometimes ‘near daily use’).
emcdda.europa.eu
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Executive summary
Cannabis use is relatively common in the European Union (EU) and Norway, with around 
23 million people (6.8 % of all 15- to 64-year-olds) having used the drug in the past year and 
about 12 million (3.6 % of all 15- to 64-year-olds) in the last month. Although the prevalence of 
last-year cannabis use among the general population is generally stable or decreasing in many 
countries, demands for treatment in which cannabis is the primary drug continue to rise, indicating 
a possible increase in related problems. The substance is currently the most frequently mentioned 
drug by those demanding drug treatment for the first time in the EU and Norway. This suggests that, 
even though most cannabis use at the population level is likely to be transitory and at low levels, a 
significant minority of users use the substance intensively and/or for long periods of time. These 
patterns of use are reported to be associated with harms to the user and possibly with a need for 
treatment. Although this problem has been increasingly recognised, knowledge of the prevalence 
of the more intensive forms of cannabis use has been limited at the EU level.
This report brings together, for the first time in Europe, an integrated overview of the prevalence of 
intensive cannabis use, defined as daily or almost daily cannabis use (use on 20 or more days in 
the month preceding survey). Self-reported data regarding frequency of cannabis use from large, 
probabilistic, nationally representative samples of general population surveys from 20 countries, 
representing more than 83 % of the population of EU and Norway, were collected through two 
rounds of ad hoc data collection in 2004 and 2007 and through a routine, standard data 
collection instrument since 2010.
Depending on country, cannabis was used on 20 or more days by between 3.5 % and 44.1 % of 
people who had used the substance in the last month. Overall, among the 20 countries 
participating in the study, weighted by their estimated numbers of last-month cannabis users in the 
general population, the findings suggest that, on average, about 25 % of last-month cannabis users 
were daily or almost daily users of the substance. The population prevalence of daily or almost 
daily cannabis users ranged from 0.05 % to 2.6 % (among the 15–64 years olds). The weighted 
average of prevalence (weighted by population size) was 1 % in the countries that provided data.
Based on the existing information, it can be estimated that there are around 3 million daily or 
almost daily cannabis users in the EU and Norway. This is, however, a minimum estimate owing to 
possible under-reporting among survey participants and to a higher probability of frequent users 
occurring outside the sampling frame of general population surveys.
It is also important to stress that daily cannabis use is concentrated in some population groups, 
among which prevalence is considerably higher than in the total population, particularly in certain 
countries. Gender and age are among the most important factors. According to this analysis, the 
population prevalence among young adults (aged 15–34 years) was almost twice the average 
(1.9 %), and more than three-quarters of these young users were male. When combined with 
population sizes and the fact that there is a higher prevalence of daily cannabis use among young 
adults (aged 15–34), it means that probably just over half of daily cannabis users in Europe come 
from the population group of young males aged 15–34.
emcdda.europa.eu
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In conclusion, bearing in mind the limitations of the current approach (possible reporting bias, lack 
of information about intensive users in the past year who did not use daily in the month preceding 
the survey, cultural and legal differences, etc.), the exercise has confirmed the feasibility and 
usefulness of collection and analysis of daily cannabis use data at the EU level. This study presents 
the first European overview of intensive cannabis use with a solid quantification of the 
phenomenon. The value of these data can be further enhanced by interpreting the results in the 
context of other data and information, for example treatment demand data or information from 
in-depth studies.
emcdda.europa.eu
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Introduction
Cannabis is by far the most widely consumed and available illicit drug in Europe. In the 2012 
EMCDDA Annual report, it is conservatively estimated that cannabis has been used at least 
once (lifetime prevalence) by around 80.5 million Europeans: almost one in four of all 15- to 
64-year-olds. Use in the last year or in the last month is markedly lower than lifetime experience, 
although many EU countries report relatively high prevalence. It is estimated that around 
23 million (on average, 6.8 % of all 15- to 64-year-olds) and 12 million Europeans (on average, 
3.6 % of 15- to 64-year-olds) have used cannabis in the last year and last month, respectively 
(EMCDDA, 2012a).
Prevalence figures for the adult population, although useful, do not sufficiently highlight the fact that 
prevalence rates found among specific subgroups can be very different. As with most forms of drug 
use, rates of current use are likely to be higher among younger age groups and among males — 
see EMCDDA (2012b), table GPS-6, part iii and part v.
Cannabis use increased considerably among the general populations of many EU countries from 
the mid-1990s until the early 2000s, especially among young people. More recently, surveys in 
most countries have shown stabilisation or even decreases in levels of cannabis use in many 
countries (EMCDDA, 2012a).
What do the available estimates of cannabis use tell us about the number of people who are 
experiencing problems or harm through this behaviour? This is an important question for public 
health, but one which is difficult to answer. One indicator that may provide useful contextual data 
is requests for treatment by cannabis users. It is worth noting that in the past decade there has 
been a marked increase in the proportion and number of reported treatment admissions due to 
cannabis in Europe and that, during this period, a number of countries introduced specific 
programmes targeting cannabis problems. A total of 108 000 treatment admissions for cannabis 
were reported for the year 2010 (EMCDDA, 2012a) by the treatment centres reporting through 
the Reitox network (1) to the EMCDDA treatment demand indicator (TDI) (2). In addition, around 
98 000 treatment clients reported cannabis as their secondary drug (EMCDDA, 2012a). It is 
possible that this number of treatment admissions under-represents the extent of demand for 
services due to cannabis because in many EU countries the treatment centres reporting to the TDI 
data collection system are centres that focus on more chronic problem drug users (opiate or 
stimulant users and injectors). On the other hand, the data also have to be interpreted in a way 
that takes account of the fact that some countries direct individuals to treatment from criminal 
justice, education or social support systems. Moreover, in general terms, there is now a far 
greater awareness of the need for cannabis support services, which is likely to be associated 
with increased provision and a greater likelihood that problematic use will be identified and 
registered.
(1)  National focal points are the national institutions appointed by the respective Member State to act as a national 
partner to the EMCDDA.
(2)  For more information on the TDI key indicator, see the TDI key indicator gateway and the TDI Methods section of 
2011 EMCDDA Statistical bulletin.
emcdda.europa.eu
7
Prevalence of daily cannabis use 
in the European Union and Norway
Data from general population surveys indicate that many of those who have used cannabis in the 
past will have discontinued its use (EMCDDA, 2012a) and, historically, only a small number of 
individuals appear to use the drug regularly over a sustained period of time. This is still largely true, 
although there is some evidence to suggest that patterns of long-term regular use among young 
people may now be more common (Perkonigg et al., 2008). Overall, however, far less is known 
about levels or trends in the intensive use of this drug, information that is clearly important from a 
public health perspective. Thus, in addition to estimates of standard prevalence measures (lifetime, 
last year and last month), it is important to obtain estimates of more intensive cannabis use, as this 
form of use is more likely to result in adverse consequences, such as dependence or other problems 
(SAMHSA, 2012).
Choices made in the operational definition of ‘intensive cannabis use’ are important to the 
estimation of harm and risk associated with the behaviour. It should be noted that self-reported 
intensity measures need to be interpreted with caution, even in the case of use of purely 
behavioural questions in the data collection tool. Added to methodological concerns inherent to the 
use of these kinds of data is the fact that, without more detailed information on patterns of use, 
cannabis-consuming episodes and the potency of the drug consumed, such data can provide only 
a partial indicator of the exposure to pharmacologically active constituents of cannabis consumed 
over time. It is also worth noting that some of the harm associated with cannabis use may or may 
not be dose dependent, influenced by the mode of administration or the co-consumption of other 
products, such as tobacco. That said, methodological and practical difficulties mean that for 
surveillance purposes, and especially for cross-national comparisons, self-reported frequency of use 
is currently the best proxy measure to discriminate between different patterns of cannabis 
consumption with respect to their likely association with problems and harm.
In summary, then, for surveillance purposes frequency of use is likely to be a crude, but also useful 
and practical, indicator for estimating cannabis use-related problems at the population level. 
Pragmatically, daily or almost daily use (sometimes termed ‘near daily use’) is most commonly 
studied and compared with less frequent use. In the research literature, associations are reported 
with other illicit drug use; alcohol and tobacco use; driving and involvement in motor vehicle 
accidents after using cannabis; and impairments in cognitive, memory and learning performance. 
Frequent cannabis use has been found to predict some mental health disorders, including the 
development of psychotic symptoms, and has been associated with depressive and manic 
symptoms and suicides (Fischer et al., 2011).
Studies also show that daily cannabis users, perhaps unsurprisingly, are at higher risk of developing 
dependence symptoms than less frequent users. In a 2003 general population survey in the United 
States, it was estimated that almost 40 % of daily cannabis users (in the past year, defined as 300+ 
days of use) met cannabis dependence or abuse criteria according to the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (SAMHSA, 2004). In another American study, 25–50 % 
of daily users were estimated to be dependent (NIDA, 2010). Studies comparing frequent or daily 
cannabis users with and without dependence found a high level of health, mental health and 
cognitive problems in frequent users, but higher levels still in those meeting diagnostic criteria for 
dependence (e.g. Looby and Earleywine, 2007). The results of these studies suggest that estimating 
the prevalence of cannabis dependence would give a better indication of those potentially able to 
benefit from treatment interventions (even if not all of these users will seek assistance). However, 
emcdda.europa.eu
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harms may also be experienced by those not fulfilling the criteria of dependence. It is important to 
know the size of this broader group, chiefly from the point of view of planning appropriate public 
health interventions. A caveat here is that some surveys also now include additional short screening 
instruments designed to provide better measures of both dependence and problems. This 
information, when available, can usefully complement data on intensive use patterns.
Estimating the size of the population of frequent users of opioids or crack cocaine use necessarily 
requires indirect statistical methods, as large proportions of these users are not accessible in the 
usual sampling frames used in general population surveys. However, it can be argued that it is 
possible to estimate the prevalence of frequent cannabis use using the general population surveys 
methodology. The justification for this is the higher prevalence of cannabis use and the fact that it is 
generally less socially stigmatised and therefore more likely to be reported through survey methods. 
It should be noted, however, that intensive use is a more problematic behaviour to measure from a 
methodological perspective. There are a number of reasons for this, including the fact that it is 
likely to occur at lower levels and may be linked to other behaviours that might result in a lower 
participation in studies, such as school exclusion or social marginalisation. Nonetheless, whilst 
bearing in mind these methodological issues, the estimation of daily or near daily use does provide 
a useful indicator for the surveillance of potential needs and allows cross-country comparisons to 
be made, albeit with caution. In this respect, these data are obviously best interpreted in the context 
of other indicator data, in particular patterns in treatment attendance, but also other sources that 
provide insight into the levels of cannabis use within countries.
emcdda.europa.eu
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1. Methodology and data collection
The information presented in this report was collected through large, probabilistic, nationally 
representative general population surveys in 20 European countries. Information from 37 surveys 
was reported (17 of which were repeated surveys in the same countries).
Context of the surveys
The surveys from which the data were extracted were focused mostly on substance use (alcohol, 
tobacco and illegal drugs), although a small number of them were surveys of general health or 
victimisation (see Table 1).
Process of data collection
Information on frequency of cannabis use in the month preceding the survey was reported to the 
EMCDDA through a structured form in 2004 and 2007 — through voluntary ad hoc data 
collections (‘field trials’) — and by national focal points and national experts at the time of the field 
trials. From 2010, the EMCDDA began to routinely collect information on the frequency of cannabis 
use within the annual reporting of Member States (within standard table 1 on general population 
surveys (3)). Some countries that completed their general population surveys after the 2007 field 
trial but before the introduction of the routine data collection on frequency of cannabis use were 
asked to complete a form similar to that used in the 2007 field trial. There were, however, a few 
countries that collected (updated) data on the frequency of cannabis use in the past month, but 
which could not be included in this analysis because the data were not available to the EMCDDA. 
Some of these countries (e.g. Romania) have attempted to collect data on the frequency of use but 
have had to cease reporting them to the EMCDDA because of low numbers of last-month users.
Data collection instruments
The actual data collection in countries was conducted under general guidelines defined by the 
EMCDDA and national experts, which contains a set of common core items (the Handbook for 
surveys on drug use among the general population and the European Model Questionnaire 
(EMQ)). These guidelines were written to harmonise and facilitate the development of new 
questionnaires or to report core results obtained through existing national questionnaires to the 
EMCDDA (3).
The EMQ includes a variable on frequency of cannabis use, defined as the number of days on 
which the drug was used in the last 30 days. It can be collected as a simple number of days or 
(3)  For more information on methodologies of general population surveys, please see the General population surveys 
key indicator gateway, especially the Handbook for surveys on drug use among the general population and 
2012 EMCDDA Statistical bulletin, ‘Methods and definitions’ section of the general population surveys area.
emcdda.europa.eu
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categories of ranges of frequency (20 days or more, 10–19 days, 4–9 days, 1–3 days). Before 
2002, the Handbook suggested corresponding verbal categories (daily or almost daily, several 
times a week, once a week or more, less than once a week). These were still in use in many 
countries at the time of data collection (see Table 1).
Definition of daily cannabis use
For the purpose of this report, ‘daily cannabis use’ has been defined as the use of cannabis on 20 
days or more in the last 30 days prior to data collection. This frequency of use could be more 
precisely called ‘daily or almost daily use’, but here the two terms are used as equivalents.
Estimation of the prevalence of daily cannabis use
The prevalence of cannabis use on 20 days or more in the month preceding survey is estimated in 
most countries by combining the last-month prevalence with the proportion of last-month users who 
used on 20 days or more in the same month. As both parameters are weighted (4), the result is 
equivalent to direct estimation of prevalence. In two countries (Ireland and the UK) the national 
experts have estimated directly the prevalence of daily cannabis use because the primary data 
were not available to the reporting expert.
EU estimates of parameters of daily cannabis use
In addition to presenting the national data, the proportion of daily users among last-month users, 
the average prevalence of daily use and the total number of daily users in the EU and Norway 
were estimated by the EMCDDA.
(4)  The parameters are weighted by basic population characteristics so that they are nationally representative for the 
countries that provided the EMCDDA with data.
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Table 1.  General population surveys in the EU and Norway: most recent survey available with collection of data on the frequency of cannabis 
use in the last month and/or last-month prevalence of cannabis use. All EMCDDA countries are included
Countrya
Survey 
year
Context of survey Mode of data collection Wording of the cannabis frequency question 
Last-month prevalence 
of cannabis use 
(15–64 years) (%)
Belgiuma 2008 Health Face-to-face interview with self-administered 
questionnaire completed on paper for substance use 
questions
EMQ-b 3.1
Bulgaria 2008 Alcohol, tobacco, drugs 
and attitudes 
Face-to-face interview Not asked 1.4
Czech 
Republica
2008 Alcohol, tobacco, drugs Face-to-face interview How often have you taken cannabis in the last 30 days?
1. Daily or almost daily (5–7 days a week)
2. Several times a week (3–4 days a week)
3. At least once a week
4. Less than once a week
8.6
Denmarka 2010 Health Self-administered questionnaire, with possible 
web-based completion
EMQ-c 2.3
Germanya 2009 Addiction (licit and illicit 
drugs, pathological 
gambling)
Multimode; mail, telephone, Internet Number of days 2.4
Estonia 2008 Work/family/leisure/
health/drugs
Mail Verbal categories 1.4
Irelanda 2006/07 Alcohol, tobacco, drugs Face-to-face interview (CAPI) EMQ-c 2.6
Greecea 2004 Health Face-to-face interview Number of days 0.9
Spaina 2009 Alcohol, tobacco, drugs Face-to-face interview with self-administered 
questionnaire completed on paper for drug use 
questions
1–3 days; 4–9 days; 10–19 days; 20–29 days; 30 days; 
I have not taken cannabis or marijuana in the last 30 days; 
I have never taken cannabis or marijuana
7.6
Francea 2010 Health Telephone interview (CATI) Number of times 4.8
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Countrya
Survey 
year
Context of survey Mode of data collection Wording of the cannabis frequency question 
Last-month prevalence 
of cannabis use 
(15–64 years) (%)
Italya 2008 Alcohol, tobacco, drugs Mail On how many occasions have you taken cannabis? Never; 
1–2 times; 3–5 times; 6–9 times; 10–19 times; 20–39 
times; 40 or more times
6.9
Cyprusa 2009 Alcohol, tobacco, drugs 
and health
Mail EMQ-b 2.5
Latviaa 2003 Alcohol, tobacco, drugs, 
lifestyle and attitudes
Face-to-face interview with self-administered 
questionnaire completed on paper for substance 
use.
EMQ-a 1.8
Lithuaniaa 2008 Alcohol, tobacco, drugs, 
lifestyle and attitudes
Face-to-face interview with self-administered 
questionnaire completed on paper for substance use
EMQ-a 1.2
Luxembourg Old survey
Hungarya 2007 Substance use (licit and 
illicit, including 
behavioural addictions)
Face-to-face interview with self-administered 
questionnaire completed on paper for substance use
At least 20 times/10–19 times/4–9 times/1–3 times/
haven’t used it
1.2
Malta 2001 Alcohol, tobacco, drugs Face-to-face interview Not collected 0.5
Netherlandsa 2005 Household living 
conditions
Face to-face interview (CAPI) Verbal categories 3.3
Austriaa 2008 Alcohol, tobacco, drugs Face-to-face interview Number of days 1.7
Poland 2006 Alcohol, tobacco, drugs Face-to-face interview Not available 0.9
Portugala 2007 Alcohol, tobacco, drugs Face-to-face interview (CAPI) Verbal categories 2.4
Romania 2007 Alcohol, tobacco, drugs Face-to-face interview with self-administered 
questionnaire completed on paper for substance use
Too few last-month users to be able to process the data 0.1
Slovenia 2011 Health Face-to-face interview EMQ-c Not available
Slovakiaa 2010 Alcohol, tobacco, drugs Face-to-face interview Verbal categories 1.4
Finlanda 2006 Drug use and alcohol 
drinking patterns
Mail Number of days 1.6
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Countrya
Survey 
year
Context of survey Mode of data collection Wording of the cannabis frequency question 
Last-month prevalence 
of cannabis use 
(15–64 years) (%)
Sweden 2010 Public health Mail Not collected 1.0
United 
Kingdom 
(England 
and Wales)a
2010/11 Crime and victimisation Face-to-face interview (CASI) for substance use Verbal categories 3.9
Norwaya 2009 Alcohol, tobacco, drugs Face-to-face interview with self-administered 
questionnaire completed on paper for substance use
EMQ-c but within last 4 weeks 1.6
Data are reported by national focal points to the EMCDDA on structured online forms, by drug, timeframe (lifetime prevalence, last-year prevalence and last-month prevalence), gender and age group. 
More detailed methodology of each national survey, including sample size and procedures, methods of data collection and related references, are presented in EMCDDA (2012b), in particular 
Table GPS-121 and GPS-1.
a Included in the analysis of daily cannabis use prevalence, presented in this Thematic paper.
CAPI, computer-assisted personal interview; CASI, computer-assisted self-interview; CATI, computer-assisted telephone interview.
EMQ-a, verbal categories of ‘Daily or almost daily’, ‘Several times a week’, ‘At least once a week’ and ‘Less than once a week’; 
EMQ-b, numbers of day categories of 20 days or more, 10–19 days, 4–9 days and 1–3 days; 
EMQ-c, number of days.
emcdda.europa.eu
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2. Results
Data tables
Table 2 presents an overview of results for ‘all adults’ in the standard age range of 15–64 years. In 
a few countries the age ranges for all adults differed slightly. Data from 37 nationally 
representative surveys conducted between 1998 and 2011 are presented. Most (26) of these 
surveys were conducted between 2005 and the present.
The number of respondents for each national survey is presented. In most cases it was possible to 
also obtain a weighted number of people reporting use of cannabis in the last month. In most 
surveys, the number of users in the last month was over 100, and in some cases even over 1 000. 
However, in a few surveys the estimated number of last-month users is lower than 50 (owing to 
limited sample size and/or low last-month prevalence of cannabis) and the results should be 
interpreted with caution.
Table 3 presents the most recent data reported by each of the 20 countries on frequency of 
cannabis use for all adults (15–64 years in most countries). Data from most (18) countries are from 
2005 or later. The populations of these countries account for more than 83 % of the EU population 
aged 15–64 years.
Table 4 presents the most recent data reported by 20 countries for young adults (15–34 years in 
most countries). The total number of respondents in this age group and the weighted number of 
cases reporting cannabis use in the last 30 days are presented. Results on young adults are 
presented because cannabis use is concentrated in this age group.
Last-month prevalence of cannabis use
In the 20 countries that took part in the data collection on daily cannabis use, last-month 
prevalence of cannabis use in the population aged 15–64 years ranged from 0.9 % in Greece to 
8.6 % in the Czech Republic (see Table 3). An average, weighted by population size of the 20 
countries, was 4.2 %. This amounts to roughly 11 740 000 cannabis users in the last month in those 
countries, over 96 % of the estimated total last-month cannabis users in the EU and Norway. As 
these countries represent just over 83 % of the population of the EU and Norway, and the average 
prevalence of all countries was 3.6 % (see above and 2012 EMCDDA Annual report), this indicates 
that the present analysis includes countries with higher prevalence of past-month cannabis use and 
misses countries with a low prevalence (see also Table 1 for last-month prevalence of cannabis use 
in countries where data on daily cannabis use were not available).
15
Prevalence of daily cannabis use 
in the European Union and Norway
emcdda.europa.eu
Table 2.  Surveys for which daily cannabis use information has been reported to the EMCDDA
Country Survey year
Number of 
last-month users
Net response (valid 
number of 
respondents)
All adults (standard age range 15–64 years)
Actual age range
Last-month 
prevalence of 
cannabis use (%)
% of daily or almost 
daily users (20 days 
or more) among 
last-month users
Prevalence of daily 
use among all adults 
(%)
Belgium 2008   204  6 792 15–64 3.1 29.4 0.9
Czech Republic 2004   170  3 526 15–64 4.8  7.2 0.3
Czech Republic 2008   385  4 500 18–64 8.6  9.1 0.8
Denmark 2005   187  8 956 16–64 2.6 15.9 0.4
Denmark 2010   262 11 611 16–64 2.3 20.6 0.5
Germany 2003   371  8 061 18–64 3.4 23.4 0.8
Germany 2009   184  8 030 18–64 2.4 16.8 0.4
Ireland 2002/03   126  4 925 15–64 2.6 22.5 0.6
Ireland 2006/07 n.a.  4 918 15–64 2.6 24.4 0.6
Greece 1998   104  3 398 15–64 2.3 19.5 0.5
Greece 2004    39  4 781 15–64 0.9 12.3 0.1
Spain 2001 1 058 14 113 15–64 6.8 33.6 2.3
Spain 2005 2 460 28 324 15–64 8.7 31.0 2.7
Spain 2009 1 518 20 109 15–64 7.6 33.9 2.6
France 2000   497 11 317 15–64 4.4 26.4 1.1
France 2005 1 222 25 879 15–64 4.8 32.4 1.6
France 2010 1 032 22 774 15–64 4.6 33.3 1.5
Italy 2001   171  6 032 15–64 4.7 19.3 0.8
Italy 2005 1 534 27 995 15–64 5.8 17.6 1.0
Italy 2008   679 10 940 15–64 6.9 24.4 1.7
Cyprus 2006    47  3 504 15–64 1.4 13.0 0.2
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Country Survey year
Number of 
last-month users
Net response (valid 
number of 
respondents)
All adults (standard age range 15–64 years)
Actual age range
Last-month 
prevalence of 
cannabis use (%)
% of daily or almost 
daily users (20 days 
or more) among 
last-month users
Prevalence of daily 
use among all adults 
(%)
Cyprus 2009    84  3 385 15–64 2.5 22.6 0.6
Latvia 2003    81  4 534 15–64 1.8  5.4 0.1
Lithuania 2008   268  4 777 15–64 1.2  6.1 0.1
Hungary 2007    30  2 579 18–64 1.2 21.4 0.3
Netherlands 2000/01   744 14 045 15–64 3.7 23.6 0.8
Netherlands 2005   150  4 516 15–64 3.3 23.0 0.8
Austria 2004   144  3 980 15–64 3.8 25.7 1.0
Austria 2008    56  3 354 15–64 1.7 11.1 0.2
Portugal 2001   335 14 184 15–64 2.4 23.2 0.6
Portugal 2007   293 12 202 15–64 2.4 44.1 1.1
Slovakia 2006 n.a.  2 020 15–64 2.0 – –
Slovakia 2010    57  4 055 15–64 1.4  3.5  0.05
Finland 2010    25  1 873 15–64 1.4 13.0 0.5
United Kingdoma 2005/06 n.a. 29 932 16–59 5.2 – –
United Kingdom 2010/11 n.a. 27 452 16–59 3.8 15.0 0.6
Norway 2004    57  2 575 15–64 2.2 12.7 0.3
Norway 2009    18  1 624 15–64 1.6 16.7 0.3
For more details on surveys, their methodology and results see EMCDDA 2012b, section on general population surveys.
a In the 2005/06 survey for the United Kingdom (England and Wales, British Crime Survey) the question on frequency of cannabis use was posed only to the 16- to 24-year-old age group, but it is 
imputed to the 16- to 34-year-old group. In this survey the frequency of use was assessed for the last 12 months.
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Table 3.  Most recent survey available in each country reporting data on daily cannabis use
Country Survey year
Number of 
last-month users
Net response (valid 
number of 
respondents)
All adults (standard age range 15–64 years)
Actual age range
Last-month 
prevalence of 
cannabis use (%)
% of daily or almost 
daily users (20 days 
or more) among 
last-month users
Prevalence of daily 
use among all adults 
(%)
Belgium 2008   204  6 792 15–64 3.1 29.4 0.9
Czech Republic 2008   385  4 500 18–64 8.6  9.1 0.8
Denmark 2010   262 11 611 16–64 2.3 20.6 0.5
Germany 2009   184  8 030 18–64 2.4 16.8 0.4
Ireland 2006/07 n.a.  4 918 15–64 2.6 24.4 0.8
Greece 2004    39  4 781 15–64 0.9 12.3 0.1
Spain 2009 1 518 20 109 15–64 7.6 33.9 2.6
France 2010 1 032 22 774 15–64 4.6 33.3 1.5
Italy 2008   679 10 940 15–64 6.9 24.4 1.7
Cyprus 2009    84  3 385 15–64 2.5 22.6 0.6
Latvia 2003    81  4 534 15–64 1.8  5.4 0.1
Lithuania 2008   268  4 777 15–64 1.2  6.1 0.1
Hungary 2007    30  2 579 18–64 1.2 21.4 0.3
Netherlands 2005   150  4 516 15–64 3.3 23.0 0.8
Austria 2008    56  3 354 15–64 1.7 11.1 0.2
Portugal 2007   293 12 202 15–64 2.4 44.1 1.1
Slovakia 2010    57  4 055 15–64 1.4  3.5  0.05
Finland 2010    25  1 873 15–64 1.4 13.0 0.5
United Kingdom 2010/11 n.a 27 452 16–59 3.8 15.0 0.6
Norway 2009    18  1 624 15–64 1.6 16.7 0.3
For more details on surveys, their methodology and results see EMCDDA (2012b), section on general population surveys.
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Table 4.  Most recent survey available in each country reporting data on daily cannabis use — data on young adults (aged 15–34 years)
Country Survey year
Number of 
last-month users
Net response (valid 
number of 
respondents)
Young adults (standard age range 15–34 years)
Actual age range
Last-month 
prevalence of 
cannabis use (%)
% of daily or almost 
daily users (20 days 
or more) among 
last-month users
Prevalence of daily 
use among young 
adults (%)
Belgium 2008 109 2 550 15–34  6.9 31.7 2.2
Czech Republic 2008 316 1 892 15–34 16.7  9.5 1.6
Denmark 2010 111 3 381 16–34  5.1 13.3 0.7
Germany 2009  93 3 876 18–34  5.4 16.5 0.9
Ireland 2006/07 n.a. n.a. 15–34  4.2 25.0 1.8
Greece 2004  33 2 620 15–34  1.5 12.0 0.2
Spain 2009 821 n.a. 15–34 14.1 33.6 5.0
France 2010 841 7 727 15–34  9.8 33.5 3.3
Italy 2008 606 6 398 15–34  9.9 19.6 1.9
Cyprus 2009  67 1 810 15–34  4.5 25.4 1.1
Latvia 2003  71 n.a. 15–34  1.8  4.3 0.2
Lithuania 2008  55 2 152 15–34  2.6  6.4 0.2
Hungary 2007  26 1 111 18–34  2.7 15.4 0.4
Netherlands 2005  76 n.a. 15–34  5.6 28.9 1.6
Austria 2008  43 1 261 15–34  3.4  9.3 0.3
Portugal 2007 203 4 765 15–34  4.5 46.8 2.1
Slovakia 2010  50 1 769 15–34  2.8  4.0 0.1
Finland 2010  23   875 15–34  1.4 14.3 0.5
United Kingdom 2010/11 n.a. 9 589 16–34  6.8 15.0 1.0
Norway 2009   9   632 15–34  2.1 11.1 0.2
For more details on surveys, their methodology and results see EMCDDA (2012b), section on general population surveys.
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Proportion of daily or almost daily users among people who used 
cannabis in the last month
Twenty countries reported data on daily cannabis use among all adults (aged 15–64; see Table 3). 
Depending on the country, cannabis was used on 20 days or more by 3.5 % (Slovakia in 2010) to 
44.1 % (Portugal in 2007) of respondents who had used the substance in the last month. The 
average prevalence in the 20 countries, weighted by the estimated numbers of last-month cannabis 
users in the general populations of each country, was 24.8 %.
The remaining cannabis users reported using the substance on 10–19 days (on average 14.6 %), 
4–9 days (17.8 %) or 1–3 days (45 %) in the previous month. Figure 1 shows the distribution of 
last-month cannabis users across the groups defined by frequency of cannabis use.
Figure 1.  Distribution of frequency of cannabis use in all adults (aged 15–64 years) 
who have used the drug in the last month, by country
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Prevalence of daily or almost daily cannabis use
Among all adults (15–64 years), prevalence ranged from 0.05 % (Slovakia) to 2.6 % (Spain, see 
Table 3), with a median of 0.55 %. Interquartile range was 0.6 % (the first quartile being 0.25 % 
and the third quartile 0.85 %).
The weighted average of prevalence (weighted by population size) was 1 %.
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Among young adults (15–34 years), prevalence ranged from 0.1 % (Slovakia) to 5 % (Spain; 
see Table 4). The median was 0.95 %. The interquartile range was 1.65 % (the first quartile being 
0.2 % and the third quartile 1.85 %).
The weighted average of prevalence (weighted by population size of the countries taking part in 
the analysis) was 1.9 %.
Applying these prevalence rates to the population sizes of corresponding age gives an estimate of 
over two-thirds (around 70 %) of daily cannabis users in European countries being in the age group 
15–34 years.
The role of gender
The prevalence of daily cannabis use by gender (among young adults only) is presented in 
Figure 2. Prevalence in young males is considerably higher than in their female peers. In some 
countries, 3.0–7.5 % of young males are daily cannabis users. In the 17 countries where 
information is available and sample sizes are sufficient, males would account for more than 
three-quarters of daily cannabis users in the age group 15–34 years. This, combined with 
population sizes and the fact that there is a higher prevalence of daily cannabis use among young 
adults (aged 15–34, see above), means that probably just over half of daily cannabis users in 
Europe come from the population group of young males aged 15–34.
Figure 2.  Prevalence of last-month daily cannabis use among 15- to 34-year-olds 
by gender
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Changes over time
In the 15 countries for which more than one data point was available, data suggest a relatively 
stable prevalence of daily cannabis use overall. Applying approximate confidence intervals to the 
estimates, it appears that an increase probably occurred in Portugal whereas decreases probably 
occurred in Germany, Austria and the United Kingdom (among the 15- to 34-year-olds in the latter 
case) (5).
Estimation of the prevalence of daily cannabis use in the EU and 
Norway
In the 20 countries providing data, it can be estimated that there are approximately 2 960 000 
daily users. For the rest of the EU countries, representing less than 17 % of the total EU population, 
information on last-month cannabis use prevalence is available, corresponding to approximately 
444 000 users (6). Assuming that, among these past-month users, the proportion of daily users will 
be equivalent to that in countries providing data (i.e. 24.8 %), a simple calculation yields an 
estimate of around 110 000 daily cannabis users in these countries, making an estimated total of 
over 3 million (7) daily cannabis users in the EU and Norway.
(5) Over 4- to 6-year periods. Only data collected after 2000 were taken into account in this analysis.
(6)  With the exception of Slovenia, where only last-year prevalence is available. However, by applying the EU 
average proportion of last-month users to the figure for last-year users (50 %), an approximate total figure can be 
derived for the purpose of this rough calculation.
(7)  This would be lower than an estimate obtained by applying average population prevalence of daily cannabis 
users in the countries providing data (just over 1 %) to the entire EU and Norway population, giving a figure of 
around 3.5 million. However, the estimate provided above would probably be more accurate, given that countries 
not reporting data on daily cannabis use are, in general, those with lower or much lower prevalence of last-month 
cannabis use.
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3.  Discussion: strengths and limitations of the data 
on daily cannabis use in Europe
The estimates of daily or almost daily cannabis use presented in this report are useful but do have 
limitations. In particular, comparisons between countries need to be made with caution because of 
some differences in data collection methods and survey instruments used (see Table 1).
The resulting EU estimates cannot be attached to a particular year. The data from which they were 
derived correspond mostly to the period 2005–10 (although for a number of countries, including 
the most populated countries, the surveys correspond to the years 2009–10). However, countries 
with more recent results were those with higher prevalence, and therefore limiting the analysis to 
more recent years would probably overestimate EU prevalence due to these non-at-random missing 
data. Moreover, although the national surveys were not conducted in the same year, their estimates 
appear relatively stable during consecutive years in most countries with repeated surveys during the 
examined time period. The same applies to last-month prevalence of cannabis use in cases where 
data on daily cannabis use were not available.
In addition, cultural differences, particularly those impacting on the willingness to report cannabis 
use, are likely to exist. It is reasonable to assume that (downwards) reporting biases may be more 
pronounced in countries where the use of the drug is most stigmatised, and there is probably an 
association between levels of stigmatisation and prevalence of use. These limitations apply to both 
national and EU estimates. It is, however, worth noting that the national estimates of daily cannabis 
use are obtained using the same basic methodological principles: nationally representative 
population surveys with generally large sample sizes (see Table 2) in which information is self-
reported and data collection scales are relatively well harmonised. Also, it is not likely that the 
above-mentioned cultural differences will result in over-reporting (the possible bias is in only a 
downwards direction), so the overall estimate can be understood in this context.
The estimates are derived from a sample of those reporting cannabis use in the last month, and thus 
will not include those who have been using the drug on a daily basis in the last year but not 
consumed it (near) daily in the month prior to interview. Thus, more research is needed to 
understand whether and how the estimates can be interpreted in relation to the annual prevalence. 
Annual prevalence of intensive cannabis use would be relevant from the point of view of 
understanding prevalence of related harms in the corresponding time frame (e.g. dependence, 
harmful use). On the other hand, 1-year prevalence would suffer from a higher recall bias. In this 
respect, the recall period of ‘last month’ should, as a rule, give a more precise result.
This exercise does demonstrate that data collection on daily cannabis use using general population 
surveys is feasible and it permits an estimate to be made from surveys currently covering around 
83 % of the EU’s population.
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